Promising New Agents for Treatment of Patients with Colorectal Cancer

Overview

Journal Semin Oncol

Specialty Oncology

Date 1998 Oct 24

PMID 9786316

Citations 3

Authors

D D Von Hoff

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer continues to be a major problem. There are a number of new agents with promising clinical activity, including the multitargeted antifolate LY 231514 and the thymidylate synthesis inhibitor capecitabine. In addition, other agents have shown promising preclinical activity against the disease: 6-hydroxymethylacylfulvene (HMAF; MGI 114), LY 295501, bizelesin (U-7779; NSC615291), and ONYX-015. Finally, several agents may prevent colorectal cancer through prevention of the formation of colorectal polyps (eg, cyclooxygenase inhibitors).

Citing Articles

Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells.

Thant A, Wu Y, Lee J, Mishra D, Garcia H, Koeffler H Anticancer Res. 2009; 28(6A):3579-92.

PMID: 19189638 PMC: 3771536.

Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience.

Correale P, Cusi M, Micheli L, Nencini C, Del Vecchio M, Torino F Invest New Drugs. 2006; 24(2):99-110.

PMID: 16502353 DOI: 10.1007/s10637-006-5932-7.

A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.

Correale P, Messinese S, Caraglia M, Marsili S, Piccolomini A, Petrioli R Br J Cancer. 2004; 90(9):1710-4.

PMID: 15150625 PMC: 2409742. DOI: 10.1038/sj.bjc.6601783.